{"url_path":"/sec/dwtx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-061938-index.html","accession_number":"0001104659-26-061938","cik":"0001818844","ticker":"DWTX","issuer_name":"Dogwood Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-061938-index.html","primary_entity_key":"0001818844","primary_entity_name":"Dogwood Therapeutics, Inc."},"word_count":483,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nSee Exhibit Index.\n\n​\n\n​\n\n38\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n​\n\n​\n\nEXHIBIT INDEX\n\n​\n\n**Exhibit********No.**\n\n**  ​ ​ ​**\n\n**Description**\n\n​\n\n10.1\n\n​\n\n[Form of Purchase Agreement (incorporated by reference herein from Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/dwtx-20260109xex10d1.htm)\n\n​\n\n​\n\n​\n\n10.2\n\n​\n\n[Form of Pre-Funded Warrants (incorporated by reference herein from Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/dwtx-20260109xex10d2.htm)\n\n​\n\n​\n\n​\n\n10.3\n\n​\n\n[Form of Common Stock Warrants (incorporated by reference herein from Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/dwtx-20260109xex10d3.htm)\n\n​\n\n​\n\n​\n\n10.4\n\n​\n\n[Form of Registration Rights Agreement (incorporated by reference herein from Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/dwtx-20260109xex10d4.htm)\n\n​\n\n​\n\n​\n\n10.5\n\n​\n\n[Form of Placement Agency Agreement (incorporated by reference herein from Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/dwtx-20260109xex10d5.htm)\n\n​\n\n​\n\n​\n\n31.1†\n\n​\n\n[Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](dwtx-20260331xex31d1.htm)\n\n​\n\n31.2†\n\n​\n\n[Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](dwtx-20260331xex31d2.htm)\n\n​\n\n32.1†\n\n​\n\n[Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](dwtx-20260331xex32d1.htm)\n\n​\n\n32.2†\n\n​\n\n[Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](dwtx-20260331xex32d2.htm)\n\n​\n\n​\n\n​\n\n101.INS†\n\n​\n\nXBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n​\n\n101.SCH†\n\n​\n\nXBRL Taxonomy Extension Schema Document\n\n​\n\n101.CAL†\n\n​\n\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n​\n\n101.DEF†\n\n​\n\nXBRL Taxonomy Extension Definition Linkbase Document\n\n​\n\n101.LAB†\n\n​\n\nXBRL Taxonomy Extension Label Linkbase Document\n\n​\n\n101.PRE†\n\n​\n\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n​\n\n​\n\n​\n\n104†\n\n​\n\nCover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)\n\n†\n\nFiled herewith.\n\n​\n\n​\n\n​\n\n39\n\n[Table of Contents](#TOC)\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.\n\nDate: May 15, 2026\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**DOGWOOD THERAPEUTICS,**** ****INC.**\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ Greg Duncan\n\n​\n\nName:\n\nGreg Duncan\n\n​\n\nTitle:\n\nChairman of the Board of Directors and Chief Executive Officer\n\n​\n\n​\n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ Angela Walsh\n\n​\n\nName:\n\nAngela Walsh\n\n​\n\nTitle:\n\nChief Financial Officer, Corporate Secretary and Treasurer\n\n​\n\n​\n\n(Principal Financial and Accounting Officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n40"}